作为抗生素输送系统的先进的富血小板纤维素 (A-PRF):体外验证概念研究
Giorgio Serafini1, Alessia Mariano2, Marco Lollobrigida1
1Department of Oral and Maxillo Facial Sciences, "Sapienza" University of Rome, Via Caserta, 6, 00161 Rome, Italy.
Materials (Basel, Switzerland)
|February 13, 2025
概括
先进的富血小板纤维素 (A-PRF) 可以有效地在局部提供抗生素. 这项研究表明,A-PRF维持了阿莫西西林和甲化的持续释放,抑制了细菌生长,并可能减少了全身抗生素的使用.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 自主血小板缩物,如高级血小板丰富纤维素 (A-PRF),因其生长因子和细胞含量而用于再生疗法.
- 低速离心产品A-PRF提供更高的生长因子和细胞度以及比白细胞和血小板丰富纤维素 (L-PRF) 更宽松的纤维素结构.
研究的目的:
- 评估A-PRF作为抗生素氨基西林 (AMX) 和甲基醇 (MTZ) 的局部输送系统的潜力.
- 评估纳入A-PRF凝块中的抗生素的持续释放特征和抗菌疗效.
主要方法:
- 在不同度的抗生素 (AMX和MTZ) 中测试了A-PRF血栓形成,选择了0.5 mg/mL.
- 用抗生素丰富的A-PRF凝块在PBS中化,并在24小时,72小时,7天和14天内分析抗生素释放.
- 微生物学分析确定了 *Fusobacterium nucleatum* 和 *Prevotella intermedia* 的细菌生长抑制区.
主要成果:
- 氨基西林 (AMX) 在14天内表现出一致的释放 (24小时平均19.9±4.8 ng/mL),没有显著的患者间变化.
- 甲尼达 (MTZ) 的释放变化较大 (24小时平均12.8±4.5 ng/mL),并且随着时间的推移逐渐减少.
- 观察到显著的细菌生长抑制区域:24小时后AMX (23毫米为*F. nucleatum*,34毫米为*P. intermedia*) 和MTZ (28毫米为*F. nucleatum*,30毫米为*P. intermedia*)
结论:
- A-PRF作为一种有效的局部抗生素输送系统,提供持续释放和抗菌活性.
- 这种方法可以减少在某些治疗背景下对全身抗生素的必要性.
- 进一步的研究可以探索优化A-PRF配方,以在再生医学中提供向的抗生素.
相关概念视频
01:22Formation of the Platelet Plug
3.9K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
3.9K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
461
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
461